Last updated: February 16, 2026
Development Status of Intepirdine
Intepirdine, a 5-HT6 receptor antagonist, was developed by Axovant Sciences for cognitive impairment associated with Alzheimer's disease. It entered late-stage clinical trials but failed to meet primary endpoints, leading to a halt in its development.
Clinical Trial Outcomes
- Phase 3 trials, GRAIN and SUNRISE, assessed efficacy in mild to moderate Alzheimer's disease.
- Both trials published results indicating no significant cognitive benefit compared to placebo.
- The Sunstone trial, designed to replicate earlier positive signals, also did not demonstrate efficacy.
- Despite promising early-phase data, subsequent extensive trials showed failure to achieve primary endpoints.
Withdrawal and Current Status
- Axovant discontinued further development of Intepirdine for Alzheimer's after trial failures in 2019.
- No ongoing or planned clinical trials for this indication as of 2023.
- Development for other indications appears inactive, with no recent patent filings or company updates.
Patent Landscape
- Original patents covering Intepirdine issued around 2012, expiring roughly in 2032.
- Secondary patents claiming formulations or specific uses may extend patent life into the early 2030s.
- No recent patent applications indicate active pursuit of new indications.
Market Projection
Market Size and Opportunities
- Alzheimer's disease patients worldwide estimated at 55 million in 2020.
- The global Alzheimer's therapeutics market reached USD 8.9 billion in 2021.
- Estimated annual growth rate of approximately 5% through 2028.
Market Influence
- The failure of Intepirdine in pivotal trials significantly affects its commercialization prospects.
- Cognitive enhancers and anti-dementia drugs with proven efficacy dominate current markets.
- Intepirdine's principal competition consists of cholinesterase inhibitors (donepezil, rivastigmine) and NMDA receptor antagonists (memantine).
Commercial Outlook
- No current commercial pathway for Intepirdine as a cognitive enhancer for Alzheimer's.
- Potential redevelopment for other indications is limited due to weak patent protection and lack of clinical efficacy.
- Market shift towards disease-modifying therapies (e.g., aducanumab) reduces the attractiveness of symptomatic agents like Intepirdine.
Market Entrants and Competition
| Drug |
Mechanism |
Approval Status |
Market Share (2022) |
| Donepezil |
Cholinesterase inhibitor |
Approved worldwide |
~50% |
| Memantine |
NMDA receptor antagonist |
Approved worldwide |
~20% |
| Aducanumab |
Anti-Aβ monoclonal antibody |
Approved in US, limited in others |
Emerging |
Future Market Outlook
- Drugs similar to Intepirdine face diminishing returns due to repeated clinical failures.
- Certain 5-HT6 antagonists initially showed promise but failed in late-stage studies.
- The focus is shifting to disease-modifying agents rather than symptomatic treatments.
Conclusions
- Intepirdine is effectively abandoned for Alzheimer's therapy following Phase 3 trial failures.
- Its patent landscape remains active but unlikely to support new indications given lack of efficacy.
- The Alzheimer's therapeutics market continues to evolve toward precision and disease-modifying approaches, leaving little room for reintroduction of failed symptomatic agents.
Key Takeaways
- Intepirdine has no current clinical development for Alzheimer’s or other indications.
- Market prospects for Intepirdine are negligible post-failure, with no near-term pathways to approval.
- The Alzheimer's disease market is dominated by proven therapies, with increasing preference for disease-modifying agents.
- Patent protection extends into the early 2030s, but commercial viability without efficacy data is uncertain.
- Future efforts in 5-HT6 receptor antagonists face significant hurdles due to repeated clinical failures.
FAQs
1. Why did Intepirdine fail in clinical trials?
Clinical trials showed Intepirdine did not produce significant cognitive benefits in patients with Alzheimer's, failing to meet primary endpoints despite promising early data.
2. Is there any ongoing development for Intepirdine?
No. Axovant and other developers ceased development initiatives in 2019 following trial failures, and no new trials are ongoing or planned.
3. Could Intepirdine be repurposed for other indications?
Re-purposing is unlikely without new positive clinical data. The failure to demonstrate efficacy for Alzheimer's diminishes prospects for other uses.
4. How does Intepirdine's patent landscape impact future potential?
Patents extend into 2032, which could theoretically support development if efficacy was proven. Current market realities make re-entry improbable.
5. What is the outlook for 5-HT6 receptor antagonists in neurodegenerative diseases?
The class faces significant setbacks due to late-stage trial failures, reducing enthusiasm and investment for new compounds targeting these receptors.
Sources
[1] ClinicalTrials.gov. (2019). "Intepirdine (SB-742457) in Alzheimer’s Disease."
[2] Axovant Sciences. (2019). "Press release on Phase 3 trial results."
[3] MarketsandMarkets. (2022). "Alzheimer's Disease Therapeutics Market."
[4] PatentScope. (2023). Patent filings related to Intepirdine.
